41 results
Page 2 of 3
8-K
EX-99.2
fd4vn8ywh
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.2
w12cwmi5diupi5fy
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
49k96 a5j
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
fbyb txppo
2 Mar 21
Regulation FD Disclosure
8:00am
8-K
EX-99.1
330dfxllgqrh4ivuyp
4 Jan 21
Aravive Announces Board Member Transition to Advisory Role
4:11pm
8-K
EX-99.2
bbpp0t
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
titgbmqz85j8t9vzr
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
20glnjbncd99ikgtb
5 Nov 20
Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
4:31pm
8-K
EX-99.1
4jltt8roxbxyz
3 Aug 20
Aravive Reports Second Quarter 2020 Financial Results and Provides Recent Corporate Updates
4:10pm
8-K
EX-99.1
9djne 4bu3ac9idbn
23 Jul 20
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500
7:05am
S-4
uj9oe
3 Aug 18
Registration of securities issued in business combination transactions
5:26pm
10-K
pmwh8 i7ef
6 Mar 15
Annual report
12:00am
424B4
25r6y
22 Jan 15
Prospectus supplement with pricing info
12:00am
424B4
44rebvj sn
21 Mar 14
Prospectus supplement with pricing info
12:00am